## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.56)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Vinva Investment Management Ltd**
- Source: MarketBeat | 20251130T133630 | Somewhat-Bullish | Relevance: 100%
- Vinva Investment Management Ltd increased its stake in Zimmer Biomet Holdings, Inc. by 42.9% in the second quarter, now owning 12,514 shares valued at $1.145 million. Institutional investors collectively own 88.89% of the stock, while corporate insiders hold 1.39%, with SVP Lori Winkler recently selling 1,500 shares. Analysts currently have an average "Hold" rating and a consensus price target of $109.00 for the company, which recently beat EPS estimates and provided positive FY2025 guidance.

**2. Jefferies Financial Group Inc. Sells 21,687 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251129T105454 | Neutral | Relevance: 99%
- Jefferies Financial Group Inc. significantly reduced its stake in Zimmer Biomet Holdings, Inc. by selling 21,687 shares, retaining 6,800 shares worth $620,000. This comes as other large institutional investors like Ameriprise and JPMorgan Chase & Co. have substantially increased their positions, while Zimmer Biomet reported Q3 earnings that beat estimates but revenue slightly missed, with FY2025 guidance set. Analyst ratings for ZBH are mixed, with a consensus "Hold" rating and an average target price of $109.00.

**3. Laurel Wealth Advisors LLC Has $1.13 Million Position in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251130T115138 | Somewhat-Bullish | Relevance: 97%
- Laurel Wealth Advisors LLC significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9,021.3% to a total of 12,405 shares valued at $1.13 million. This increase comes as Zimmer Biomet reported strong Q3 earnings, beating EPS estimates, and provided positive FY2025 guidance. Institutional investors hold a significant portion of the company's stock, and analysts maintain a consensus "Hold" rating with a $109 price target.

**4. Zimmer Biomet Holdings, Inc. $ZBH Stock Position Decreased by JPMorgan Chase & Co.**
- Source: MarketBeat | 20251130T104147 | Neutral | Relevance: 97%
- JPMorgan Chase & Co. significantly decreased its stake in Zimmer Biomet Holdings, Inc. by 55.4% in the second quarter, selling over 1.1 million shares. Despite this, other institutional investors increased their holdings, and the company reported strong Q2 EPS, beating analyst estimates. Analysts currently rate the stock as "Hold" with a consensus price target of $109.00.

**5. Cetera Investment Advisers Raises Stock Holdings in Invesco S&P MidCap 400 Pure Value ETF $RFV**
- Source: Defense World | 20251201T043424 | Neutral | Relevance: 63%
-  Cetera Investment Advisers significantly increased its stake in the Invesco S&P MidCap 400 Pure Value ETF (RFV) by 408% during the second quarter, holding 17,720 shares valued at $2,142,000. Several other institutional investors also adjusted their holdings in RFV. The article notes that RFV stock opened at $130.29 on Friday, with a market cap of $286.64 million.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 11.1x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.4B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 11.1 |
| Current P/E | 11.6 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.7% (minimal 5-day change). Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 (-1.9%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.96x), long-term trend not supportive. MACD histogram positive (1.05), confirming momentum. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.70% (CS: 70) | Neutral |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | 1.05 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 0.956x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $94.76
- **Stop Loss:** $89.56 (5.5% risk)
- **Target:** $105.16 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 144
- **Position Value:** $13,645.44
- **Portfolio %:** 13.65%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*